by admin | Sep 7, 2018 | Stem Cell Therapy
Multipotent stem cells have the ability to turn into a number of different cells in the body, making them one of the most versatile solutions in regenerative medicine. They are also characterized by their capacity for self-renewal. Here, we take a look at their current applications, as well as their benefits.
What Makes Multipotent Stem Cells Unique?
To understand the distinguishing features of multipotent stem cells, we must first look at the different types of stem cells. There are three main classifications for the varying degrees of stem cell flexibility:
- Totipotent: These cells can turn into any cell in the body and are only found within the first couple of cell divisions following the fertilization of a female egg by a male sperm.
- Pluripotent: During embryonic development, totipotent cells specialize into pluripotent cells. They can give rise to all cells in the human body but aren’t quite as flexible as totipotent cells.
- Multipotent: Finally, pluripotent stem cells specialize into multipotent stem cells, which have been found in cord blood, cord tissue, adipose tissue, cardiac cells, bone marrow, and mesenchymal stem cells (MSCs).
What Are Multipotent Stem Cells Used for?
Not only are multipotent stem cells able to renew themselves almost indefinitely, their ability to become any other cell makes them a powerful agent in treating patients with tissue damage. From knees to other joints and even the gastrointestinal tract, there are many sites in the body where compromised tissue can benefit tremendously from stem cells. They can even help arthritis sufferers and individuals with tendonitis. Because stem cells can also replenish dying or damaged tissue of specialized cell types, multipotent stem cells can also benefit individuals with chronic illnesses such as COPD, multiple sclerosis (MS), and Parkinson’s disease.
What Are the Benefits of Multipotent Stem Cells?
Multipotent stem cells are advantageous because they can be sourced from a number of locations, including the Wharton’s Jelly which lines umbilical cord vessels, as well as fat tissue (adipose stem cells) and bone marrow aspirate. These cells can then be delivered via non-invasive regenerative therapy to replace damaged cells with new ones, which have the ability to help increase energy and control symptoms in chronic conditions. The treatment can also potentially spur healthy tissue development in musculoskeletal injuries, and when injected directly into the joint, it has the potential to promote healing of ligaments, tendons, and cartilage to help return functionality and in some cases could delay the need for joint replacement.
by admin | Aug 31, 2018 | Stem Cell Research, Stem Cell Therapy, Studies
Crohn’s disease is a chronic inflammatory bowel disease that has no cure. It causes abdominal pain, frequent diarrhea, weight loss, fatigue, and anemia. While the disease can be controlled to some degree through oral and injectable medications, life-threatening complications may occur.
One of the feared complications of Crohn’s disease is called a bowel fistula. A fistula is an abnormal connection between two places on the body. In Crohn’s disease, a fistula forms between the intestine and some other structure—the intestine essentially forms a “tunnel.” The fistula can form between one loop of intestine and another, between intestine and bladder, or even between the intestine and the outside of the body. This complication of Crohn’s disease is obviously quite distressing to patients.
Some bowel fistulas may close on their own with conservative treatments, but fistulas associated with Crohn’s disease do not respond well to available medical treatments. Those looking for an alternative treatment may be able to consider stem cell therapy.
Stem cells offer an interesting potential solution to this problem. Stem cells can provide a large dose of normal cells filled with molecules that can help direct normal bowel growth and development. Indeed, researchers have shown that autologous mesenchymal stem cells can help close and heal fistulas in patients with Crohn’s disease.
In phase I, II, and IIB clinical trials, stem cells derived from adipose tissue or bone marrow were directly infused into the bowel area (via a so-called intra-fistular injection). Across five clinical studies including over 100 patients, stem cell administration resulted in complete fistula healing in 50 to 80% of patients treated. Of those who did not obtain complete control fistula closure, almost all had evidence of improvement. These results support that autologous mesenchymal stem cell therapy is a promising future treatment for patients with Crohn’s disease and may offer patients enjoy a better quality of life.
by admin | Aug 28, 2018 | Stem Cell Research, Stem Cell Therapy
The evidence for the promise of mesenchymal stem cells in regenerative medicine has been growing for several years. With new sources regularly emerging, stem cells can come from a large variety of sources. Postnatal mesenchymal stem cells appear to have the most promise in regeneration. A new review has addressed how mesenchymal stem cells can be used with innovative scaffolding engineering approaches to improve techniques in regenerative medicine.
Mesenchymal stem cells are, on their own, good candidates for regeneration because of a number of characteristic features. For instance, they can differentiate into many different types of cells. Osteoblasts and chondroblasts are two cell types that mesenchymal stem cells differentiate into and that can be supported in bone regeneration by 3D-printed biomaterials like scaffolds.
Mesenchymal stem cells also can have beneficial impacts on the immune system. Unlike with other stem cell types, the severe immune reactions that may occur with the transplantation of foreign materials into the body can often be avoided with the use of mesenchymal stem cells, making them a safe option in regenerative medicine.
The current review addresses the ways in which bone regeneration can be optimized through the use of mesenchymal stem cells and scaffold engineering and how new concepts in bioengineering may be able to improve regenerative medicine in combination with mesenchymal stem cell approaches. Future research will need to focus on how we can customize regenerative approaches using what we know about mesenchymal stem cells and the most cutting-edge innovations in bioengineering.
by admin | Aug 21, 2018 | Stem Cell Therapy, Wharton's Jelly
Mesenchymal stem cells have been showing promise in the treatment of a variety of diseases and injuries. These cells are derived from different tissue types, and it appears that where the stem cells come from is indicative of how they function and how appropriate they are for use in different applications. Bone marrow-derived mesenchymal stem cells have been deeply studied and are often considered a go-to for stem cell research and clinical use.
However, there are several limitations that bone marrow-derived mesenchymal stem cells pose, particularly from a practicality standpoint, and thus, researchers have begun to try to understand how other types of stem cells may achieve similar or better results than those from the bone marrow. A recent review, published in Act Histochemical, compiled comprehensive data on the biological properties associated with a specific type of mesenchymal stem cell called Wharton’s Jelly-derived mesenchymal stem cells.
These stem cells, which come from the umbilical cord, are able to differentiate into mature cells that make up several different types of tissues and can even turn into non-mesenchymal cells, such as neurons, or brain cells. They are useful in that they spontaneously move to sites of injury or inflammation and may, therefore, be able to help restore tissue and normal functioning. They are also unlikely to instigate adverse immune system reactions.
While it is advantageous that bone marrow-derived mesenchymal stem cells have been studied extensively and therefore are associated with broad knowledge of therapeutic applicability, the cells are difficult to isolate and use. In contract, cells from the umbilical cord matrix, or Wharton’s jelly, are easy to isolate and also appear to be good candidates for therapeutic intervention. Future research should therefore look more closely at how Wharton’s jelly-derived mesenchymal stem cells can be used to treat disease and injury. As noted by the authors of this review, there are specifically dysfunctions of the central and peripheral nervous system that these stem cells may be able to address.
by admin | Aug 10, 2018 | Bone Marrow, Wharton's Jelly
Mesenchymal stem cells that come from different cell sources can look similar but behave differently. Bone marrow-derived mesenchymal stem cells tend to be the gold standard for isolating and using mesenchymal stem cells, it is not particularly easy to access these cells from the bone marrow. Because there are other, much more easily accessible mesenchymal stem cells, such as those from the umbilical cord, it is important to establish the differences between the different types of stem cells so that each can be used when most appropriate and when most advantageous.
One important difference is how to isolate the cells and how easy it is to do so. Recent work published this year in Stem Cells and Development helped to define the best way to isolate mesenchymal stem cells from the Wharton’s jelly of umbilical cords. The researchers also looked at the gene expression profile and the immune system characteristics of both bone marrow-derived mesenchymal stem cells and Wharton’s jelly-derived mesenchymal stem cells.
The researchers found that mesenchymal stem cells that came from the Wharton’s jelly of the umbilical cord had a better capacity to expand into more tissue than those taken from the bone marrow. Further, their gene expression was different. In the stem cells from the Wharton’s jelly, there was greater gene enrichment for genes related to cell adhesion, proliferation, and immune system functioning than in the cells from the bone marrow. These cells also induced the maturation of brain cells more so than did the mesenchymal stem cell derived from bone marrow.
These results show that Wharton’s jelly-derived mesenchymal stem cells have distinct properties from bone marrow-derived mesenchymal stem cells and likely have specific advantages as well to help treat those battling osteoarthritis, multiple sclerosis, Parkinson’s disease, and other degenerative conditions. Further research will help bear out more of the differences between these types of stem cells and how each type can best be used to help patients.
St. Petersburg, Florida
